Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Mutlu Hızal

7PUBLICATIONS
27CO-AUTHORS
Molecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

Sort by Publication Date:
|Nov 22, 2025
Talazoparib in patients with BRCA mutant metastatic breast or ovarian carcinoma: results of early access program.

Mehmet Ali Nahit Sendur, Mutlu Hizal, Burcu Çakar

|May 03, 2023
Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer.

Seda Kahraman, Enes Erul, Mustafa Seyyar

|Sep 01, 2022
The percentage of ALK-positive cells and the efficacy of first-line alectinib in advanced non-small cell lung cancer: is it a novel factor for stratification? (Turkish Oncology Group Study).

Mutlu Hizal, Burak Bilgin, Nail Paksoy

|Jun 23, 2022
Real-world data on efficacy and safety of first-line alectinib treatment in advanced-stage, ALK-positive non-small-cell lung cancer patients: a Turkish Oncology Group study.

Mutlu Hizal, Burak Bilgin, Nail Paksoy

|Nov 02, 2021
Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.

Emre Yekedüz, İsmail Ertürk, Deniz Tural

|Jul 31, 2021
The real-life efficacy and safety of osimertinib in pretreated advanced non-small cell lung cancer patients with T790M mutation: a Turkish Oncology Group Study.

Mutlu Hizal, Burak Bilgin, Nail Paksoy

Pageof 2

Frequent Collaborators

2 joint publications

Gokhan Ucar

2 joint publications

Yüksel Ürün

2 joint publications

Seda Kahraman

2 joint publications

Deniz Tural

1 joint publications

Hatime Arzu Yasar

1 joint publications

Dilek Erdem

1 joint publications

Tuğba Akın Telli

1 joint publications

Naziye Ak

1 joint publications

Nadiye Akdeniz

1 joint publications

Enes Erul

Frequent Collaborators

2 joint publications

Gokhan Ucar

2 joint publications

Yüksel Ürün

2 joint publications

Seda Kahraman

2 joint publications

Deniz Tural

Top Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

7.8K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on : Jun 13, 2014

16.8K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

8.0K
See more related videos

Top Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on : Jul 25, 2020

7.8K
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
14:20

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on : Jun 13, 2014

16.8K
Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
09:38

Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib

Published on : Jun 26, 2019

8.0K
See more related videos